704-05-2

Basic information

• Product Name: 4-FLUORO-2-NITRO-N-METHYLANILINE
• Synonyms: BUTTPARK 45\09-95;4-FLUORO-2-NITRO-N-METHYLANILINE;N-METHYL-4-FLUORO-2-NITROANILINE;4-Fluoro-N-Methyl-2-nitroaniline
• CAS NO: 704-05-2
• Molecular Formula: C₇H₇FN₂O₂
• Molecular Weight: 170.14
• Mol File: 704-05-2.mol

Chemical Properties

• Melting Point: 76 °C(Solv: hexane (110-54-3))
• Boiling Point: 275.8±30.0 °C(Predicted)
• Appearance: /
• Density: 1.361±0.06 g/cm3(Predicted)
• PKA: -0.80±0.25(Predicted)
• CAS DataBase Reference: 4-FLUORO-2-NITRO-N-METHYLANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-FLUORO-2-NITRO-N-METHYLANILINE(704-05-2)
• EPA Substance Registry System: 4-FLUORO-2-NITRO-N-METHYLANILINE(704-05-2)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 704-05-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Fluoro-2-nitro-N-methylaniline is used as a key intermediate in the synthesis of various pharmaceuticals, contributing to the development of new drugs with potential therapeutic applications.
Used in Dye Industry:
4-FLUORO-2-NITRO-N-METHYLANILINE is utilized as a building block in the production of dyes, which are essential for coloring textiles, plastics, and other materials.
Used in Polymer Industry:
4-Fluoro-2-nitro-N-methylaniline is employed in the synthesis of polymers, which have a wide range of applications in various industries, including automotive, electronics, and packaging.
Used in Agricultural Products:
As an intermediate, 4-Fluoro-2-nitro-N-methylaniline is used in the production of agricultural products, such as fertilizers and plant growth regulators, to enhance crop yield and quality.
Used in Insecticide Production:
4-FLUORO-2-NITRO-N-METHYLANILINE is also used in the synthesis of insecticides, which are crucial for controlling pests and protecting crops from damage.

Upstream product

• 364-74-9 1,4-difluoro-2-nitrobenzene 
• 593-51-1 methylamine hydrochloride 
• 364-78-3 2-nitro-4-fluoroaniline 
• 655-56-1 N-methyl-N-(4-fluorophenyl)nitramine 
• 446-35-5 2,4-Difluoronitrobenzene 
• 74-89-5 methylamine 
• 128691-91-8 2,2,2-trifluoro-N-(4-fluoro-2-nitrophenyl)acetamide 
• 77-78-1 dimethyl sulfate 

Downstream Products

• 401567-10-0 4-fluoro-N₁-methylbenzene-1,2-diamine 
• 1365271-95-9 5-fluoro-1-methyl-1H-benzo[d]imidazole 
• 401567-12-2 2-chloro-5-fluoro-1-methyl-1H-benzimidazole 
• 401567-11-1 5-fluoro-1-methyl-1,3-dihydro-2H-benzo[d]imidazole-2-one 
• 401567-11-1 5-fluoro-1-methyl-1H-benzimidazol-2-ol 

Relevant articles and documents

Cu-Catalyzed C-H Allylation of Benzimidazoles with Allenes

CuH-catalyzed intramolecular cyclization and intermolecular allylation of benzimidazoles with allenes have been described. The reaction proceeded smoothly with the catalytic system of Cu(OAc)2/Xantphos and catalytic amount of (MeO)2MeSiH. This protocol features mild reaction conditions and a good tolerance of substrates bearing electron-withdrawing, electron-donating, or electron-neutral groups. A new catalytic mechanism was proposed for this copper hydride catalytic system.

1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to 1,3,4-oxadiazole derivative compounds having a histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, a use thereof in preparation of a medicament, a pharmaceutical composition comprising the same, a therapeutic method using the composition, and a method for preparing the same, and the 1,3,4-oxadiazole derivative compounds are represented by a following chemical formula (I).

TRANSGLUTAMINASE 2 (TG2) INHIBITORS

Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit transglutaminase 2 (TG2). Also described herein are methods for using such TG2 inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from TG2 inhibition.

Photoreactivity of monofluorinated 2-azidobenzimidazoles towards carboxylic acids

Aiming at the development of new photolabeling agents, the synthesis and photoreactivity of all monofluorinated derivatives of 2-azido-1-methylbenzimidazole are described. In the case of 4-, 5-, or 7-fluorination, irradiation in the presence of carboxylic

COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR-ANTAGONISTS

The present invention relates to new medicament combinations which contain in addition to one or more PDE4-inhibitors (1) at least one EP4 receptor antagonist (2), as well as the use thereof for the treatment of preferably respiratory complaints such as particularly COPD, chronic sinusitis and asthma. The invention relates in particular to those medicament combinations which contain at least one EP4 receptor antagonist (2), in addition to one or more, preferably one, PDE4 inhibitor of general formula 1 wherein X is SO or SO2, but preferably SO, and wherein R3 denotes an optionally substituted, mono- or bicyclic, unsaturated, partly saturated or saturated heterocyclic group or an optionally substituted, mono- or bicyclic heteroaryland wherein R1 and R2 have the meanings given in claim 1, the preparation thereof and the use thereof for the treatment of respiratory complaints.

HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE

The present invention provides a novel hydroxyquinoxaline carboxamide derivative that is useful for preventing and/or treating blood coagulation disorders. A compound represented by formula (i), or a pharmacologically acceptable salt thereof: wherein, each of R1 and R2 independently represents a group such as a hydrogen atom or a halogen atom; R3 represents a group such as a hydrogen atom; each of R4 and R5 independently represents a group such as a hydrogen atom, a halogen atom or a C1-4 alkyl group; each of R6 and R7 independently represents a hydrogen atom or a C1-4 alkyl group; X represents a group such as a C3-10 cycloalkyl group, C6-10 aryl group or a 5- to 10-membered heterocyclic group, which may be substituted with substituent(s) selected from substituent group α; Y represents a group such as -CO-, -O- or -NRa-, and Ra represents a group such as a hydrogen atom or a C1-4 alkyl group.

HETEROCYCLE-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES

The invention relates to new dihydrothienopyrimidinesulphoxides of formula 1, as well as pharmacologically acceptable salts thereof, wherein X is SO or SO2, but preferably SO, and wherein R3 denotes an optionally substituted, mono- or bicyclic, unsaturated, partially saturated or saturated heterocycle or an optionally substituted, mono- or bicyclic heteroaryl and wherein R1 and R2 have the meanings stated in claim 1, as well as pharmaceutical compositions which contain these compounds. These new dihydrothienopyrimidinesulphoxides are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers.

Medicament Combinations for the Treatment of Respiratory Diseases

The present invention relates to new medicament combinations which contain in addition to one or more, preferably one compound of general formula 1 wherein A, B, R1, X, n and m may have the meanings given in the claims and in the specification, at least one other active substance 2, processes for preparing them and their use as pharmaceutical compositions.

Novel Enantiomeric Pure Beta Agonists, Manufacturing and Use as a Medicament Thereof

The present invention relates to enantiomerically pure compounds of formula 1 wherein the groups m, n, B, X, R1, m and Ym- may have the meanings given in the claims and specification, methods for preparing them and their use as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.

New betamimetics for the treatment of respiratory complaints

The present invention relates to compounds of formula 1 wherein the groups n, m, B, X and R1 may have the meanings given in the claims and specification, processes for preparing them and their use as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.